A Galactolipid Possesses Novel Cancer Chemopreventive Effects by Suppressing Inflammatory Mediators and Mouse B16 Melanoma

Chia-Chung Hou, Yi-Ping Chen, Jyh-Horng Wu, Chi-Chang Huang, Sheng-Yang Wang, Ning-Sun Yang, and Lie-Fen Shyur

Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, Republic of China and Department of Forestry, National Chung-Hsing University, Taichung, Taiwan, Republic of China

Abstract

Crassocephalum rabens (Asteraceae) is a popular anti-inflammatory folk medicine and food supplement. We investigated the cancer chemopreventive bioactivity of C. rabens phytocompounds in vitro and in vivo using cell- and gene-based bioassays and a mouse B16 melanoma model. The bioactive glyceroglycolipid 1,2-di-O-α-linolenyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG) that was identified from C. rabens was found in vitro and in vivo to be a potent nitric oxide (NO) scavenger. dLGG treatment inhibited both mRNA and protein expression of inducible NO synthase and cyclooxygenase-2 (COX-2) in murine macrophages and inhibited COX-2 gene transcription in 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated B16 cells. In immunohistochemical studies, dLGG inhibited TPA-induced expression of COX-2 and nitration of proteins in mouse skin. dLGG could also significantly inhibit lipopolysaccharide-induced prostaglandin E2 production in murine macrophages. Furthermore, dLGG prevented nuclear translocation of cytoplasmic nuclear factor-κB (NF-κB) by suppressing IκBα phosphorylation and degradation. Structure-activity relationship studies by electrophoretic mobility shift assay indicated that the dilinolenoylglycerol moiety in dLGG is the essential structural feature preventing NF-κB-DNA complex formation. A dLGG-enriched extract from C. rabens (10 mg/kg) markedly suppressed B16 melanoma growth in C57BL/6J mice following i.p. administration, an effect comparable with that of cisplatin, a cancer chemotherapeutic drug. This study shows the detailed molecular mechanism(s) underlying the anti-inflammatory and tumor-suppressive effects of a natural galactolipid.


Introduction

Cancer chemoprevention concerns the use of natural or synthetic substances, alone or as a mixture, to reduce the risk of development or recurrence of cancer (1, 2). In recent years, the anticancer potential of many phytocompounds has been shown in vitro or in vivo in animal models (3); polyphenols in the leaves of tea (Camellia sinensis), for example, inhibits tumorigenesis and tumor growth (4, 5). The pressing need for such anticancer agents has spurred the search for phytocompounds from other sources and with novel modes of action.

Nitric oxide (NO) and its metabolite, peroxynitrite, are mutagenic because they can deaminate DNA and inactivate DNA repair enzymes (6, 7). NO is produced by the oxidative deamination of L-arginine at inflammatory sites by inducible NO synthase (iNOS), which is expressed in response to a variety of proinflammatory cytokines and bacterial lipopolysaccharide (LPS; refs. 8, 9). Improper expression of iNOS has been associated with the pathophysiology of certain human cancers and inflammatory disorders (10). Cyclooxygenase-2 (COX-2) is another important enzyme in the pathophysiology of inflammation and carcinogenesis (11, 12) through its synthesis of the precursors of prostaglandins and thromboxanes. COX-2 is expressed within human tumor neovasculature as well as in neoplastic cells in human prostate, colon, breast, and lung cancer tissues (13, 14). Because inflammation is closely linked to tumor promotion, substances with potent anti-inflammatory activities are also anticipated to have chemopreventive effects on carcinogenesis (15), especially selective inhibitors of both COX-2 and iNOS (16, 17).

Nuclear factor-κB (NF-κB), one of the principal inducible transcription factors in mammals, plays a pivotal role in inflammation through regulation of COX-2 and iNOS expression (10). NF-κB signaling involves an integrated sequence of protein-regulated steps, many of which are potential targets for inflammation and cancer treatments. NF-κB is maintained as an inactive cytoplasmic form through its association with an inhibitory molecule IκB. Exposure of cells to a variety of external stimuli, including cytokines, radiation, LPS, and reactive oxygen species, causes rapid phosphorylation of IκB, with subsequent dissociation and proteosomal degradation, allowing activated free NF-κB dimers to translocate to the nucleus (18) and induce transcription of many target genes (19). Several phytocompounds have been shown to inhibit COX-2 and iNOS expression by blocking improper NF-κB activation (20, 21). The NF-κB pathway provides exciting incentives to search for novel active phytocompounds in medicinal plants (22).

Crassocephalum rabens (Asteraceae) is a popular herbal medicine and food supplement in Taiwan for various inflammation-related syndromes. As there was no information about the truth of this reputation, we investigated in vivo and in vitro the anti-inflammatory and cancer chemopreventive properties of extracts and purified phytocompounds from C. rabens. We report here that a major galactolipid component, 1,2-di-O-α-linolenyl-3-O-β-galactopyranosyl-sn-glycerol (dLGG), can suppress NF-κB and its downstream inflammatory mediators, NO, iNOS, COX-2, and prostaglandin E2 (PG-E2), in vivo. The in vivo cancer prevention activity of a dLGG-rich extract from C. rabens was also examined against B16 melanoma growth in C57BL/6J mice.
Materials and Methods

Cell lines and culture conditions. RAW 264.7 and B16 cells were obtained from the American Type Culture Collection. Macrophages were grown in DMEM (Life Technologies), and B16 cells were grown at 37°C in RPMI 1640 (Life Technologies), both supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, in a humidified 5% CO₂ incubator.

Materials. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 12-O-tetradecanoylphorbol-13-acetate (TPA), LPS, DTT, sodium nitroreducyanide (SNP), and 2, phenyl-4,4,5,5-tetramethylimidazoline-1-oxide-3-oxide (PTIO) were purchased from Sigma Chemical Co. Celerecoxib (Celebrex) was from Pharmacia. Silica gel (230–400 mesh) and silica gel 60 F254 TLC and RP-18 F254s TLC plates were purchased from Merck. RP-18 silica gel (75μg–OPN) was purchased from Cosmosil. All other chemicals and solvents were of reagent or high-pressure liquid chromatography (HPLC) grade.

Animals. Female C57BL/6 mice and female ICR mice (National Laboratory Animal Center, Taipei, Taiwan) were given a standard laboratory diet and distilled water ad libitum and kept on a 12-h light/dark cycle at 22 ± 2°C.

Isolation and structure elucidation of dLGG. Approximately 5.0 kg of fresh whole C. rabens (voucher specimen CB001 in Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, Republic of China) was extracted with methanol at room temperature. Total methanol extract was partitioned with ethyl acetate to yield the ethyl acetate fraction (12.5 g), which was separated on a silica gel column with CH₂Cl₂-methanol to yield subfractions 1 to 8. Subfraction 8 was further purified on a RP-18 silica gel column eluted with 95% methanol to give a monogalactosyldiacylglycerol-enriched fraction (designated CREa8, 0.8 g). This subfraction, the most potent inhibitor of NO production in LAP-activated macrophages among the tested fractions (data not shown), was further fractionated using semipreparative RP-HPLC (Phenomenex Luna 5 μm, C18 column, 250 × 10 mm). The metabolite profile of CREa8 was characterized and the content of dLGG was determined using RP-18 HPLC. Pure dLGG (65.7% of dry weight of CREa8) had a retention time of 12 min (100% methanol, 3.0 mL/min, λ205 nm) and a 13C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker ADVANCE 500 AV spectrometer.

dLGG. The characteristics of dLGG [colorless oil; electrospray-mass spectrometry (ESI-MS) m/z 797 [M+Na]+; H and 13C NMR data (pyridine-d₅)] were consistent with previously published data (23). Atmospheric pressure chemical ionization/mass spectrometry (APCI/MS) was done using a Thermo Finnigan/LCQ Advantage mass spectrometer, running in positive ion mode.

Preparation of structural analogues of dLGG. dLGG in H₂O was incubated with β-galactosidase (Sigma Chemical) at 37°C for 2 days, and the product was extracted with ethyl acetate. The extract was evaporated to give 1,2-di-O-a-linolenoyl-sn-glycerol (dLGG, colorless oil; ESI-MS m/z 635 [M+Na]+; the structure of dLGG was confirmed using one-dimensional and two-dimensional NMR spectroscopy. dLGG (5 mg) was incubated with Rhizopus oryzae lipase [1,800 unit/5 mL in boric acid-borax buffer (pH 7.7); Sigma] at 37°C for 30 min. The reaction was stopped by the addition of 0.1 mL acetic acid and 3 mL ethanol. The solvent was evaporated and the residue was separated by preparative RP-18 HPLC with 90% methanol to obtain 2-O-a-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (2LGG, 1.2 mg) and 1-O-a-linolenoyl-3-O-β-galactopyranosyl-sn-glycerol (1LGG, 0.8 mg). The characteristics of 2LGG and 1LGG [colorless oil; ESI-MS m/z 797 [M+Na]+; H and 13C NMR data (pyridine-d₅)] were consistent with previously published data (23). Linolenic acid (LA) and stearic acid (SA) were from Sigma Chemical.

Measurement of NO production and cell viability. RAW 264.7 cells were treated with compound for 1 h and then incubated for 24 h with or without LPS. Nitrite levels in cell culture medium were determined using the Griess reaction (20, 24). Cell viability was examined using the MTT-based assay (25).

Determination of nitrate concentration in plasma. Female ICR mice were topicaly treated on their shaven back area of a 2-cm diameter (3.14 cm²/site/mouse) with vehicle control (acetone), SNP (positive control), or with dLGG or PTIO for 30 min before SNP application. Mouse plasma samples were analyzed to determine the nitrate content following a published method (26).

COX-2 activity assays. COX-2 inhibition was measured using the chemiluminescent COX inhibitor screening assay kit (Cayman Chemical).

Measurement of PGE₂ production. PGE₂ production was determined according to the procedure of Chang et al. (20). Macrophages were pretreated with aspirin (500 μg/mL, 3 h) to inactivate endogenous COX-1, washed, and incubated with test compounds for 1 h before further incubation for 16 h with or without LPS. PGE₂ in the culture medium was determined with ACE competitive enzyme immunoassay (Cayman Chemical).

Reporter gene constructs and luciferase assays. Four chimeric luciferase reporter genes containing either the full-length 5’ flanking promoter region (∼1334/1) or the truncations —646/1, —320/1, and —247/1–1 bp regions of the human COX-2 promoter were constructed in the pGL3-Basic vector (Promega) by a published method (20). Another series of promoter constructs with specific mutations on the consensus sequences cyclic AMP–responsive element (CRE), NF-IL6, and NF-κB of full-length COX-2 promoter were also created using PCR-based site-directed mutagenesis (27). Primer pairs for the mutations had the following sense strand sequences: CRE (—193/—187), 5’-GAAGACGTATTACCTCATACATGC-3’; NF-IL6 (—266/—258), 5’-CACCGGGCTATGTCATCTTTTTTTTGGG-3’; NF-κB (—363/—343), 5’-CAGGAGAGTGGCCTACATCCCCCTGGT-3’; and NF-κB (—587/—572), 5’-CGCAGGAGACATTCTGCCCACCCC-3’. A double-mutated COX-2 promoter containing mutations on both NF-κB sites was also constructed (for construct maps, see Fig. 2A). pGL3-Basic vector was used as a negative control in luciferase assays. COX-2 reporter activity in arbitrary units was normalized to that for the Renilla luciferase reporter.

Reverse transcription-PCR analysis. For each reverse transcription-PCR (RT-PCR) analysis, 2 μg of total RNA isolated using Trizol reagent were used to synthesize first-strand cDNA using SuperScript II Reverse Transcriptase (Invitrogen). The ΔΔNS and COX-2 genes were amplified and analyzed using specific oligonucleotide primers and PCRs by a published method (20).

Western blotting. Total cellular proteins and the specific cytosolic and nuclear proteins were prepared using methods published elsewhere (20, 21). Protein content was measured by the Bradford method (Bio-Rad). Protein was resolved by 5% to 20% gradient SDS-PAGE and subjected to immunoblotting using enhanced chemiluminescence reagents (Amersham). Monoclonal antibodies against poly(ADP-ribose) polymerase (PARP; Transduction Laboratories), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Biogenesis), α-tubulin (Oncogene Science), COX-2 (Cayman Chemical), phospho-IκBα (Ser32), IKKα (Ser18), IKKβ (Ser18), New England Biolabs), IκBα, IκBα, IKKα/β, or NF-κB p65 (BelA Santa Cruz Biotechnology) were used.

Immunoprecipitation and IKK kinase assay. Whole-cell lysates (300 μg) of macrophages were precluated with incubation with 0.25 μg IgG and 20 μL protein A/G plus agarose beads (Santa Cruz Biotechnology) for 30 min at 4°C. Supernatants were then collected and incubated with IκKα/β antibody and protein A/G plus agarose beads at 4°C overnight. Precipitates were washed with immunoprecipitation buffer and kinase buffer. IKK kinase assay was assayed by adding 1 μg glutathione S-transferase (GST)-IκBα fusion protein (Santa Cruz Biotechnology) and 200 μL/mL ATP in 20 μL kinase buffer for 30 min at 30°C and then stopped by Laemmli’s loading buffer and heated at 100°C for 5 min. Samples were subjected to immunoblotting.

Immunohistochemical study of COX-2 and nitrotyrosine protein expressions in mouse skin. Female ICR mice were topicaly treated on their shaven backs with vehicle (acetone), TPA, or SNP for 4 h or treated with compound (dLGG, celerecoxib, or PTIO) topicaly for 30 min before treating with TPA or SNP for 4 h and finally killed by cervical dislocation. The formalin-fixed, paraffin-embedded skin tissues were stained according to the procedure of Chiang et al. (20).

Electrophoretic mobility shift assay. Electrophoretic mobility shift assay (EMSA) was done with the LightShift Chemiluminescent EMSA kit (Pierce Biotechnology). Four micrograms of nuclear extract were incubated...
**Figure 1.**

A, 1, effect of dLGG on LPS-induced NO production in RAW 264.7 cells. Cells (2 x 10^5 cells per well) seeded in 96-well plates were treated with or without the indicated concentrations of test compound in 0.5% DMSO (vehicle control) for 1 h, and then LPS (1 µg/mL) was added and incubated for 24 h. NO in the culture medium was measured using the Griess reagent. Survival of macrophages after treatment was measured using MTT assay and calculated by the following formula: viable cell number (%) = A₅₇₀ (treated cell culture) / A₅₇₀ (vehicle control) x 100. One-way ANOVA was used to analyze significance of differences. Different letters indicate significant difference (P < 0.0001).

A, 2, effect of dLGG on SNP-induced NO levels in mouse plasma. Female ICR mice were transdermally treated with 200 µL acetone (vehicle control) or SNP (5.96 mg/site) only for 15 min or pretreated with dLGG (10 mg/site) or PTIO (3.5 mg/site) for 30 min before SNP treatment. Different letters indicate significant differences among groups (P < 0.05).

B, 1, effect of dLGG on LPS-induced iNOS mRNA expression in RAW 264.7 cells. Cells were treated with the indicated concentrations of dLGG for 1 h, and then LPS (1 µg/mL) was added for 6 h. Total cellular RNA was subjected to RT-PCR, and final PCR product was resolved by 1% agarose gel electrophoresis.

B, 2, effect of dLGG on LPS-induced iNOS protein expression in RAW 264.7 cells. Cells were treated with the indicated concentrations of dLGG for 1 h, and then LPS (1 µg/mL) was added for 18 h. Total cellular protein (20 µg) was then subjected to immunoblotting. Quantification of iNOS mRNA and protein expression involved normalization to GAPDH (internal control) by densitometry.

C and D, effect of dLGG on the enzymatic activity of COX-2, PGE2 production, and COX-2 protein expression in RAW 264.7 cells. C, 1, test compounds were incubated with COX-2 enzyme and substrates and measured for COX-2 activity. Celecoxib was used as a positive control. 2, RAW 264.7 cells (1 x 10^4 cells per well) were treated with dLGG and then stimulated with LPS, and PGE2 in the culture medium was then measured. Different letters indicate significant inhibition (P < 0.05). D, cells were treated with dLGG for 1 h, and then LPS (1 µg/mL) was added for 18 h. Total cellular protein (20 µg) was subjected to immunoblotting. Quantification of COX-2 mRNA and protein expression involved normalization to GAPDH by densitometry.
with biotin end-labeled NF-κB oligonucleotide, 5′-ATGTGAGGGGACTTTC-CAGGC3′, for 20 min at room temperature. The DNA-protein complexes were subjected to 5% to 10% gradient PAGE. Competition assay with unlabeled oligonucleotide (cold DNA) was done in parallel.

**Confocal microscopy study.** RAW 264.7 cells were seeded in chamber slides for 1 h and then treated with DMSO or dLGG (75 μg/mL) for 1 h, with or without LPS stimulation for an additional 90 min. Cells were fixed, permeabilized with 0.1% Triton X-100, and stained with Hoechst 33342 (DNA marker), FITC-labeled anti-r-tubulin antibody (cytoplasm marker), or rabbit anti-p65 antibody visualized with goat anti-rabbit rhodamine red-labeled secondary antibody for analysis with a Zeiss LSM 510 META confocal laser scanning microscope.

**In vivo inhibition of tumor growth.** The chemopreventive effect of the CREa8 subfraction from *C. rubens* was evaluated on tumor growth using the B16 melanoma C57BL/6J mouse system. Six-week-old animals (four groups of five mice) were used in this experiment. Group 1 mice (Sham control) were i.p. injected with 20 μL DMSO every 2 days throughout the experimental period, except that 100 μL PBS was injected on day 0. Group 4 mice (tumor control) were pretreated with DMSO every 2 days, starting from day −14, for 2 weeks, inoculated with B16 tumor cells (1 × 106 cells/100 μL PBS) s.c. on the abdominal area on day 0, and then continuously treated with DMSO every 2 days until day 21. Group 2 mice were i.p. pretreated with CREa8 (10 mg/kg body weight per dose) every 2 days, starting from day −14, for 2 weeks, s.c. inoculated with B16 tumor cells on day 0, and then continuously treated with CREa8 (i.p.) every 2 days until day 21. Group 3 mice were similarly pretreated with DMSO every 2 days for 2 weeks, inoculated with B16 tumor cells on day 0, and then treated with cisplatin (i.p.) every 2 days until day 21. The timeline diagram of this experimental design is shown in Fig. 6A. The test mice were monitored daily, and body weights and tumor size (average of two dimensions) were recorded every 2 days. At the end of the experiment (day 21), tumors were excised and weighed.

The mouse CREa8 dose (10 mg/kg body weight) in this study can be converted to a human equivalent dose (HED) based on body surface area using the following formula (Food and Drug Administration)\(^3\): HED = animal dose in mg/kg × (animal weight in kg/human weight in kg)\(^{0.33}\), where the exponent 0.33 is used to account for the difference in body surface area between mouse and human: a dose of 10 mg/kg in a 20 g mouse converts to 0.712 mg/kg in a 60 kg human.

**Statistical analysis.** Data are expressed as mean ± SD. Statistical significance of differences between treatments was determined by ANOVA with Fisher’s post hoc test. *P < 0.05* was considered to be statistically significant.

**Results**

**dLGG significantly inhibits NO production in vitro and in vivo.** The inhibition of LPS-induced NO production by *C. rubens* extracts or purified dLGG was investigated in murine RAW 264.7 macrophages by determination of nitrite level (equivalent to NO level) in culture medium 24 h after treatment. dLGG significantly inhibited NO production in RAW 264.7 macrophages by a dose-dependent manner (Fig. 1A). The IC\(_{50}\) of dLGG was ~11.4 μg/mL (14.7 μmol/L). In MTT assays, dLGG (5–20 μg/mL) did not have detectable cytotoxicity on test macrophages.

To examine the capability of dLGG to scavenge NO in vivo, we determined the plasma NO concentration in SNP-insulted mice with or without pretreatment with dLGG. Figure 1A (2) shows that the nitrite plasma concentration was significantly increased in SNP-treated mice compared with the vehicle-treated mice. This induced increase was suppressed by pretreatment with dLGG or PTIO, a known NO scavenger, suggesting that dLGG might be a potent NO scavenger in vivo.

---

\(^3\)http://www.fda.gov/cber/dllns/dose.htm
dLGG inhibits iNOS mRNA and protein expression. The effect of dLGG on iNOS mRNA and protein expression was examined in LPS-stimulated macrophages. dLGG significantly down-regulated iNOS mRNA expression, with ~56% reduction at 50 μg/mL (Fig. 1B, 1), suggesting that dLGG modulates iNOS at the transcriptional level. Immunoblot also showed significant inhibition at the protein level after an 18-h treatment. Little iNOS protein was detected at 25 to 75 μg/mL dLGG (Fig. 1B, 2). Thus, the dLGG-induced inhibition of NO production in LPS-stimulated macrophages is also mediated through suppression of both transcription and translation of iNOS.

dLGG inhibits the enzymatic activity and protein expression of COX-2 and PGE₂ production. COX-2 activity in macrophages was significantly inhibited by dLGG, with an I₅₀ of 4.15 μg/mL (Fig. 1C, 1). The I₅₀ of the nonsteroidal anti-inflammatory drug celecoxib, used as a positive control, was 0.47 dLGG at doses between 25 and 75 μg/mL (Fig. 1C, 2).

We further examined whether dLGG affects COX-2 mRNA and protein expression using RT-PCR and immunoblotting. Whereas dLGG only moderately suppressed COX-2 mRNA expression (~29% inhibition at 75 μg/mL; data not shown), COX-2 protein levels were significantly decreased in a dose-dependent manner. dLGG (50 μg/mL) suppressed LPS-induced COX-2 protein synthesis by ~60%, and at 75 μg/mL, COX-2 protein was barely detectable (Fig. 1D).

dLGG inhibits transcription of COX-2. The effect of dLGG on COX-2 gene activity in TPA-treated B16 melanoma cells was examined. To evaluate whether important cis-acting elements located in the COX-2 promoter region were affected by TPA or dLGG treatment, we constructed a series of COX-2 promoter-luciferase reporter genes, as listed in Materials and Methods (Fig. 2A). TPA-induced COX-2 promoter activity in transfected B16 cells was down-regulated by dLGG in a dose-dependent manner (Fig. 2B). At 50 or 100 μg/mL, dLGG suppressed full-length COX-2 promoter activities by 20% and 33%, respectively, compared to untreated cells. The effect of dLGG on COX-2 promoter activity was examined using GST-IκBα phosphorylation and degradation and NF-κB translocation in RAW 264.7 cells. A, cells were treated with various concentrations of dLGG for 1 h followed by LPS stimulation (1 μg/mL) for 30 min. Western blots showed that dLGG inhibited IκBα phosphorylation and degradation and NF-κB translocation in RAW 264.7 cells. B, cells were treated with various concentrations of dLGG for 1 h and then stimulated with LPS (1 μg/mL) for another 90 min. Nuclear and cytosolic fractions were prepared for immunoblotting. IKKα/β and the phosphorylated forms of IKKα/β or GST-IκBα were detected by immunoblotting. IKKα/β immunoprecipitates were prepared from total cell lysate using anti-IKKα/β antibody and subsequently subjected to IKK kinase assay using GST-IκBα as substrate. PARP (nuclear protein) and α-tubulin (cytosolic protein) were used as loading controls.
with cells treated with TPA only (100%). Reference controls aspirin (45 μg/mL) and indomethacin (15 μg/mL) suppressed COX-2 promoter activity by 19% and 28%, respectively.

The full-length COX-2 promoter was found to be highly sensitive to TPA treatment (19-fold increase in luciferase activity) in B16 melanoma cells (Fig. 2C, gray columns). Increasing promoter truncation decreased the sensitivity to TPA induction, where the −646/−1 construct showed a 1.45-fold increase in luciferase activity and the −320/−1 construct increased only 1.27-fold. The shortest construct (−247/−1) was not responsive to TPA. In the presence of 100 μg/mL dLGG, the TPA-induced luciferase activity of cells containing −1334/−1 and −646/−1 promoter constructs (Fig. 2C, black columns) was significantly smaller (65–68%; Fig. 2C). There was no difference between TPA-stimulated cells treated with dLGG (Fig. 2C, black columns) and the respective background luciferase activity of all transfected cells (Fig. 2C, white columns), showing that dLGG was able to fully inhibit any TPA-activated increases in luciferase activity.

We further examined the contribution of specific cis-acting element binding sites on the transcription of COX-2 (Fig. 2D). TPA effectively induced COX-2 promoter-directed luciferase activity in those constructs containing single or double mutations of the NF-κB or NF-κB binding sites but not the CRE mutant (Fig. 2D, gray columns). Importantly, dLGG was able to suppress this TPA-induced COX-2 promoter activity in all mutant promoter constructs (Fig. 2D, black columns), so that luciferase activity was the same as in the respective vehicle controls (Fig. 2D, white columns). These results indicate that the CRE is a critical regulatory motif for TPA-induced COX-2 transcription, whereas the CRE, NF-κB, and NF-κB binding sites might play an equally important role in dLGG inhibition of COX-2 promoter activity.

**dLGG suppresses TPA-induced COX-2 and nitrotyrosine protein production in mouse skin.** We evaluated the ability of dLGG to inhibit TPA induction of COX-2 and nitration of proteins in vivo using immunohistochemical analysis in a mouse skin system. After treatment with TPA (10 nmol in 200 μL/site) for 4 h, levels of COX-2 and of nitrotyrosine-containing proteins (immunostained brown) increased significantly in the epidermis, and these increases were significantly attenuated by dLGG in a dose-dependent manner. The inhibitory effect on COX-2 protein expression (Fig. 3A) and on nitrotyrosine-containing proteins (Fig. 3D) from dLGG at 1 mg in 200 μL/site (6.46 mmol/mL) was comparable with that of celecoxib at 10 mg in 200 μL/site (130 mmol/L).

**dLGG prevents NF-κB p65 nuclear translocation by suppressing IκBα phosphorylation and degradation.** Figure 4A shows that the LPS-induced phosphorylation of IκBα in macrophages was inhibited by dLGG as the phospho-IκBα level decreased when the concentration of dLGG rose. The inhibition of IκBα phosphorylation also prevented IκBα degradation; IκBα continued to be detected in the presence of dLGG. The distribution of NF-κB (p65) in nucleus and cytoplasm was determined using immunoblotting. A slight increase in nuclear p65 protein (1.5-fold) was detected when macrophages were treated with a low concentration of dLGG (5 μg/mL) compared with LPS alone (1.0). With higher concentrations of dLGG (25–75 μg/mL), the level of nuclear p65 decreased accordingly (Fig. 4B). Cytoplasmic levels of NF-κB (p65) were not affected by dLGG treatment of LPS-stimulated macrophages (Fig. 4B).

The effect of dLGG on NF-κB (p65) nuclear translocation was also examined by confocal microscopy. Macrophages were treated with 0.4% DMSO or 1 μg/mL LPS with or without dLGG (75 μg/mL) and stained with fluorescence-labeled antibodies against p65 (red). To distinguish nucleus from cytosol, cells were also stained with DNA-specific Hoechst 33342 (blue) and with anti-α-tubulin antibody (green). In vehicle-treated cells, p65 protein was mainly found in the cytosol of test cells (Fig. 4C). After stimulation with LPS, p65 translocated from the cytosol to the nucleus, as seen in the overlapping blue and red (purple to pink) images in the column “nucleus/p65.” This p65 nuclear translocation was dramatically inhibited by dLGG, as the stained p65 protein (red) remained in the cytoplasm (Fig. 4C).
dLGG inhibits LPS-induced degradation of interleukin-1 receptor-associated kinase-1 and IKKα/β phosphorylation and IKK kinase activity. The effects of dLGG on levels of IKKα/β and phospho-IKKα/β, the upstream kinase of IκBα in the NF-κB signaling pathway (28, 29), and the upstream kinase, interleukin-1 receptor-associated kinase-1 (IRAK-1), for activating IKK complex were examined. dLGG inhibited the LPS-induced phosphorylation of IKKα/β, whereas IKKα/β levels were little affected. In addition, dLGG inhibited IRAK-1 degradation in LPS-stimulated macrophages (Fig. 4D).

IKK enzymatic activity was also determined to confirm whether it was correlated to the inhibition of IκBα phosphorylation by dLGG. Immunoprecipitated IKK proteins obtained from control cells (±LPS/−dLGG) or cells treated with LPS + dLGG were assayed for phosphorylation of GST-IκBα (Fig. 4D). The LPS-induced enzymatic phosphorylation of IκBα (phospho-IκBα) was decreased ~42% when treated with 75 μg/mL dLGG. The levels of immunoprecipitated IKK proteins were not affected by dLGG (data not shown). This result shows that dLGG abolished IκBα phosphorylation through inhibition of phosphorylation of IkKα/β and IKK kinase.

dLGG inhibits NF-κB binding to consensus DNA sequence. We observed in EMSA that stimulation of RAW 264.7 cells with LPS triggered a consensus B DNA element binding by NF-κB (Fig. 5A). dLGG time dependently and dose dependently inhibited NF-κB-DNA binding activity: NF-κB-DNA complex levels with 75 μg/mL dLGG for 60, 90, 120, and 180 min were 0.43, 0.30, 0.16, and 0.01 times that of LPS alone (1.0), respectively, and 25 and 50 μg/mL dLGG for 90 min decreased NF-κB-DNA complex to 77% and 23%, respectively, of LPS alone (Fig. 5B). The specific binding of NF-κB to consensus DNA could be completely prevented by the addition of excess cold DNA (Fig. 5A and B).

Structure-activity relationship study of dLGG analogues. We investigated inhibition of NF-κB-DNA binding by dLGG and its structural analogues dLG, 2LGG, 1LGG, LA, and SA by EMSA. The structure of the six test compounds are shown in Fig. 5C. All compounds were tested at 100 μmol/L, a concentration that showed strong effects with dLGG. The inhibitory potencies were dLGG > 2LGG > 1LGG > LA > SA (Fig. 5D). dLGG and dLG containing dihydroxyalgalactolipid moieties almost completely inhibited NF-κB-DNA complex formation. 2LGG, 1LGG, and LA with only one linolenoyl chain were less effective than dLGG and dLG, whereas there was little or no detectable effect for SA. These results suggest that the linolenoylglycerol moiety is the essential galactolipid feature that hinders the formation of the NF-κB-DNA complex.

Inhibition of B16 melanoma growth in C57BL/6J mice by C. rabens extract. The cancer prevention efficacy of the dLGG-rich fraction (CREa8) was examined in C. rabens extract. We investigated the cancer chemotherapeutic cisplatin as a reference control. The experimental strategy is presented in the schematic diagram in Fig. 6A. Test mice treated with CREa8 (group 2; Fig. 6C) and cisplatin (group 3; Fig. 6C) showed a significant delay (days 3–7) and inhibition of tumor growth after B16 inoculation (P < 0.05). By day 7, tumors of 0.12 and 0.29 cm average size were seen in CREa8- and cisplatin-treated mice, respectively, when the tumor control mice had 0.73 cm tumors. Moreover, the average tumor sizes at day 17 in groups 2 and 3 mice were markedly reduced (P < 0.05), at only 76% and 73%, respectively, of the tumor control (Fig. 6C). For days 18 to 21, all surviving mice in the tumor control group had tumors larger than the critical size of 1.5 cm in diameter, at which point test mice were sacrificed as required by Animal Room regulations. In contrast, at the same experimental stage, three to five mice in both groups 2 and 3 had tumors <1.5 cm in diameter. Tumors were excised from all test mice on day 21. CREa8 suppressed B16 melanoma growth in vivo more than cisplatin (Fig. 6D): the tumor weight to body weight of excised tumor versus individual mouse body weight at day 21 in the four groups.

Figure 6. Effect of CREa8 (dLGG-rich fraction) on the growth of B16 melanoma tumor in C57BL/6J mice. A, schematic diagram of the experimental design of antitumor effect with use of a melanoma C57BL/6J mouse system. B, the measured body weight (g) of test mice in the four experimental groups. C, the measured B16 tumor sizes (cm) in the four mice groups (days 1–17). D, the net weight of excised tumor versus individual mouse body weight at day 21 in the four groups. *, group 1; □, group 2; ■, group 3; ○, group 4. Points, mean; bars, SD. One-way ANOVA was used to analyze significance of differences (*, P < 0.05).
weight ratio at day 21 was significantly lower in CREa8 group (19.7%; P < 0.05) than in cisplatin (25.2%) and tumor control (31.3%) groups. Although previous studies indicated that oral galactolipids are degraded and might not to be absorbed intact by rats (30) and are hydrolyzed by human pancreatic enzymes and duodenal contents (31), suggesting a low bioavailability of the unchanged form of dLGG and its derivatives, this study shows that i.p. administration of dLGG can significantly inhibit melanoma growth without mortality or body weight loss.

Discussion

The naturally abundant galactolipids are glycosylglycerolipids with two fatty acids esterified to the glycerol sn-1 and sn-2 positions and one to four galactose units at the sn-3 position. Both natural and synthetic glycosylglycerolipids have specific anti-algal (32), antiviral (33, 34), antitumor (35, 36), anti-inflammatory (37–40), and immunosuppressive (41) activities. However, the detailed molecular mechanisms of these bioactivities remained to be addressed. We discovered in this study that C. rabens plant contains a group of monogalactosyldiacylglycerols, differing in chain length and degree of unsaturation in their fatty acyl groups (e.g., C16:0, C18:1, C18:2, and C18:3), as determined by liquid chromatography-APCI/MS (data not shown). We observed that these compounds dose dependently inhibit NO production in LPS-stimulated RAW 264.7 macrophages, and the major bioactive component dLGG possesses most significant cancer chemopreventive function.

NO is an attractive therapeutic target because its overproduction has been associated with septic shock, inflammatory diseases, and diabetes. Peroxynitrite-induced protein modifications include protein oxidation or nitration of specific amino acid residues (42). Unsaturated fatty acids containing cis-alicyclic protons was suggested to undergo nitration by NO-derived species via multiple mechanisms (43) and that nitrated fatty acids are potent anti-inflammatory signaling mediators inhibiting LPS-induced secretion of proinflammatory cytokines in macrophages (44). In this light, dLGG containing two linolenic moieties may thus be a scavenger for overproduced NO. We have shown here that dLGG effectively reduced NO in LPS-stimulated macrophages and in the plasma of SNP (a NO donor)–treated mice (Fig. 1) and that dLGG also suppressed topical SNP-induced nitroprotein formation in mouse skin, with similar inhibition to PTIO, a NO scavenger (data not shown). Additionally, dLGG dose dependently inhibited iNOS mRNA and protein expression in macrophages. This is the first demonstration that a galactolipid is a potent NO scavenger in vitro and in vivo, and the reduction in NO is also partly mediated by gene and protein down-regulation of iNOS (Fig. 1).

COX-2 can foster cancer development by enhancing cellular proliferation, rendering cells resistant to apoptosis and promoting angiogenesis. The increased prostaglandin production in different types of cancers (e.g., colon, breast, and lung) is associated with increased COX-2 expression (14). In this study, inhibition of PGE2 production by dLGG in macrophages was correlated with the attenuation of COX-2 transcriptional, translational, and enzymatic activities (Figs. 1 and 2). COX-2 is an immediate early response gene; its expression is regulated at cis-acting sites by the binding of transcription factors to the COX-2 promoter via transactivation of a regulatory signal. Our COX-2 mutant studies reveal that although the CRE is the most important regulatory factor for TPA induction of COX-2 activity in B16 cells, CRE, NF-IL6, and NF-κB binding motifs all contributed to dLGG suppression of COX-2 promoter activity (Fig. 2D). TPA-induced overexpression of COX-2 protein and protein nitration were effectively suppressed by dLGG, with an efficacy comparable with celecoxib (Fig. 3A and B). These data are the first demonstration that a galactolipid is a potent COX-2 inhibitor in vitro and in vivo.

The translocation of NF-κB to the nucleus is dependent on the phosphorylation, ubiquitination, and proteolytic degradation of IkB. The nuclear NF-κB can then transactivate several immune- or inflammatory-related genes (19). We showed that the inhibitory effect of dLGG on NF-κB nuclear translocation was due to the inhibition of LPS-induced degradation of IRAK-1 and prevention of phosphorylation and degradation of IkB through inhibition of the phosphorylation of IKKα/β and IKK kinase activities (Fig. 4).

Our result shows that nuclear NF-κB DNA binding was also significantly inhibited by dLGG in LPS-stimulated macrophages. Structure-activity relationship studies revealed that galactolipids containing dilinolenoylglycerol moieties (dLGG and dLG) were the most significant inhibitors of NF-κB DNA binding. In addition, the unsaturated LA (C18:3) was more effective than SA (C18:0; Fig. 5). Similar inhibitory activity of dLGG analogues on NO production was also observed (data not shown). Therefore, we suggest that the linolenoylglycerol element of dLGG plays a critical role in preventing NF-κB transactivation and NO production in LPS-stimulated macrophages. IRAK-1 was reported to be one of the very upstream molecules activated by an adaptor protein, myeloid differentiation primary response gene 88 (MyD88), in the MyD88-dependent pathway, which leads to the translocation of NF-κB into nucleus and this in turn can regulate the expression of many genes related to proinflammatory mediators (45). We have also observed that dLGG can dose dependently suppress the binding of FITC-labeled LPS to the test macrophages (data not shown). Taken together, our results show that dLGG attenuates the activity of NF-κB and its downstream inflammatory mediators, NO, iNOS, COX-2, and PGE2, in RAW 264.7 cells stimulated with LPS, probably due to the suppression of LPS binding to LPS receptors on the cells and the down-regulation of the MyD88-dependent pathway.

Botanical preparations have been used for treatment and prevention of various human diseases throughout history. However, as the active ingredients in plants and their mechanisms of action are usually poorly understood, scientific study of the bioefficacy and pharmacologic effects of medicinal plants is urgently needed. This report provides new insight into the molecular mechanism(s) underlying the anti-inflammatory bioactivities of a natural galactolipid dLGG from C. rabens. The anti-inflammatory effects of this galactolipid might be directly responsible for its significant cancer chemopreventive activity in vivo: the growth of B16 melanoma in C57BL/6J mice was inhibited by a galactolipid-rich fraction of C. rabens, with similar efficacy to current chemotherapeutic agents.

Acknowledgments

Received 1/17/2007; revised 4/20/2007; accepted 5/16/2007.

Grant support: National Science and Technology Program for Agricultural Biotechnology (NSTP,AB) grant 945-0043 and Academia Sinica.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank High Field Nuclear Magnetic Resonance Center (National Science and Technology Program for Medical Genomics) for measurement of NMR spectra and Dr. Harry Wilson (Academia Sinica) for his careful reading of the manuscript.
References


A Galactolipid Possesses Novel Cancer Chemopreventive Effects by Suppressing Inflammatory Mediators and Mouse B16 Melanoma

Chia-Chung Hou, Yi-Ping Chen, Jyh-Horng Wu, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/14/6907

Cited articles
This article cites 44 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/14/6907.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.